Pfizer Inc. is vulnerable to the possibility that President Donald Trump will place tariffs on the European Union, where the ...

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...